Picard Medical Advances Patent Protection for Fully Implantable Artificial Heart Technology

TUCSON, Ariz., (Sept. 24, 2025) — Tucson-based Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first U.S. and Canadian commercially-approved total artificial heart, today announced the strengthening of its intellectual property portfolio with the recent grant of U.S. Patent No. 12,383,722 B2 covering systems and methods related to its next-generation SynCardia Total Artificial Heart (STAH), the “Emperor.”

This recently granted patent, relating to the apparatus, systems, and methods for enabling a next-generation total artificial heart which provides enhanced patient flexibility, builds on earlier grants U.S. Patent No. 11,918,798 B2 and U.S. Patent No. 12,121,711 B2, bringing the Company’s total number of patented claims in the United States to 34 covering its next-generation total artificial heart system. In addition, the Company holds China Patent No. 115279450 B, which extends similar protection for the fully implantable platform in that jurisdiction. The Emperor is expected to be fully implantable and provide pulsatile flow without requiring an external pneumatic driver.

“Our growing patent portfolio underscores SynCardia’s commitment to advancing our life-saving technology,” said Matt Schuster, COO of SynCardia. “The Emperor represents the future of treatment for end-stage heart failure patients. By securing 34 claims across three U.S. patents and extending protection into China, we have created a strong international foundation around our next-generation platform. Securing this patent marks an important milestone in protecting the innovation behind our fully implantable artificial heart and supports our goal for long-term market growth driven by IP-backed innovation.”

The Company expects to continue expanding its portfolio globally to safeguard the durable and efficient mechanisms, advanced electronics, long-term durability, operational efficiency, and wireless implantable features that define its next-generation platform.

“We are building the foundation for SynCardia’s future by developing the world’s first fully implantable, durable, and patient-friendly total artificial heart,” said Patrick NJ Schnegelsberg, CEO of SynCardia. “Our patent portfolio secures the path from development to commercialization and positions us to help shape the future of heart replacement worldwide.”